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Background: Thoracic endovascular aortic repair (TEVAR) is a mini-
mally invasive alternative to open repair of many thoracic aortic pathologies.
Most of the published data to date involve a relatively limited number of
individuals and follow-up. In this descriptive study, we report our midterm
outcomes of a large, decade-long, single-center TEVAR experience.
Methods: A prospectively maintained TEVAR registry and electronic
medical records at a tertiary care center were retrospectively analyzed for
patient characteristics, intraoperative details, and early and late postoperative
outcomes.
Results: From 2000 to 2009, 400 consecutive TEVARs were per-
formed using seven endograft systems (TAG, 65%; TX2, 18%; Talent, 6%;
aortic cuff, 3%; and investigational, 8%). More than 91% were performed in
the last 5 years of the study. The distribution of pathologies treated included
198 aneurysms (50%), 100 dissections (25%), 54 penetrating ulcers (13%),
25 traumatic transections (6%), and 23 other pathologies (6%). Dissections
represented the single fastest growing segment being treated. Men com-
prised 69%, the mean age was 65  16 years, and 18% had had prior
abdominal aortic replacements. Thirty-two percent of cases were performed
urgently or emergently. Sixty-nine percent were American Society of Anes-
thesiology class IV, and 61% underwent general anesthesia. Spinal drains
were prophylactically placed in 127 cases (32%) of planned extended aortic
coverage. There were no acute surgical conversions. Mean number of
devices was 2.3  1.1, and 63% of cases were completed with one or two
devices. Mean fluoroscopy was 24  15 minutes, contrast was 139  54
mL, blood loss was 309  316 mL, and procedure time was 116  5
minutes. Sixteen percent required iliac conduits. Fifty-one percent of prox-
imal landing zones involved zones 0 to 2. Preoperative adjunctive surgical
procedures were performed on 94 patients (24%). These included arch
debranching in 22 (6%), first-stage elephant trunk in 20 (5%), visceral
debranching in 21 (5%), and left subclavian revascularization in 31 (8%).
Subclavian revascularizations were selectively performed in only 17% of zone
2 deployments. The median length of stay was 5 days (range, 1-79 days).
Incidence of type I/III endoleak was 10% and 5% at 1 and 12 months,
respectively. Overall 30-day mortality was 6.5% (elective, 2.6%; urgent,
9.5%; emergent, 20%). Permanent spinal cord ischemia occurred in 3.6% and
stroke in 2.1%. Kaplan-Meier estimates of survival were 81%, 76%, and 69%,
and freedom from secondary intervention were 90%, 86%, and 82% at 6, 12,
and 24 months, respectively.
Conclusions: Since commercial availability of thoracic endografts,
TEVAR has been used to treat a variety of thoracic aortic pathologies, many
of which were off-label.With careful planning and technique, the procedures
can be performed with virtually zero risk of intraoperative conversion.
Although overall rates of mortality and neurologic complications were
relatively low, they were significantly increased in emergency repairs. There
appears to be substantial number of late deaths that may represent a
combination of poor patient selection or treatment failures.
Preoperative Thrombolysis and Venoplasty Affords no Benefit in Pa-
tency Following First Rib Resection and Scalenectomy for Subclavian
Vein Thrombosis
James L. Guzzo, Kevin Chang, Jasmine Demos, James H. Black III, and
Julie A. Freischlag, From The Johns Hopkins Hospital. Balitmore, Md
Background: Subclavian vein thrombosis is a rare presentation of
thoracic outlet syndrome (TOS). Typical treatment patterns consist of
preoperative anticoagulation, followed by operative decompression by first
rib resection and scalenectomy (FRRS). Recently, thrombolytic therapy has
been used as the initial treatment with anticoagulation and FRRS. This study
reviewed our extensive experience and compared the effectiveness of preop-
erative thrombolysis and venoplasty with anticoagulation alone in those
undergoing FRRS to preserve subclavian vein patency.
Methods: A retrospective review was conducted for all venous TOS
patients from July 2003 to May 2009 from a prospectively maintained
database. Patient demographics and use of preoperative anticoagulation,
thrombolysis, and percutaneous venoplasty were recorded. Reports of fol-
low-up venograms after FRRS were analyzed with regard to axillosubclavian
vein patency, percutaneous venoplasty, results of intervention, and presence
of occlusions. Postoperative clinic evaluations and duplex imaging reports
were reviewed for presence of symptoms, recanalization, chronic nonocclu-
sive thrombus, or continued complete occlusion.
Results: A total of 103 patients (53 men, 50 women) had 110 FRRSs
for subclavian vein thrombosis, seven of which had contralateral FRRS for
thrombosis. The average age was 31 years (range, 16-54 years), with a mean
follow-up of 13 months (range, 1-52 months). Overall before FRRS, 65
patients (59%) were managed with anticoagulation alone and 45 (41%) had
preoperative endovascular interventions. Of these 45 patients, 22 (49%)
underwent thrombolysis alone and 23 (51%) underwent thrombolysis andaxillosubclavian balloon venoplasty. After FRRS, 43 patients (96%) had
follow-up venograms 2 weeks postoperatively revealing patent subclavian
veins in 15 patients, stenosis requiring balloon dilatation in 21, and occlu-
sions in seven (16%). The overall initial patency rate in this group was 84%.
In follow-up, recanalization was documented in five of the seven occlusions,
with restoration of the patency of the subclavian vein at a mean of 2.8
months postoperatively (range, 1-6 months). In the 65 patients managed
with anticoagulation alone before FRRS, 61 (94%) underwent follow-up
venograms. The venograms revealed patent subclavian veins in 15 patients,
stenosis requiring balloon dilatation in 36, and 10 occlusions (16%). Eight of
10 occlusions were recanalized at an average of 4.3 months (range, 1-11
months) after FRRS.
Conclusions: Although initial treatment strategies for subclavian vein
thrombosis may differ, a combination of anticoagulation, thrombolysis,
operative decompression with FRRS, and postoperative endovascular inter-
ventions can yield excellent outcomes. A large proportion of patients in this
series (41%) underwent thrombolysis before operative decompression with
FRRS but showed no improvement in outcome as determined by vein
patency on postoperative venography and duplex imaging during follow-up.
Our large series suggests preoperative treatment with anticoagulation alone
has vein patency rates similar to patients undergoing thrombolytic therapy.
This treatment paradigm also has tremendous cost containment potential
given the use of outpatient anticoagulation at the initial presentation has an
obvious lower cost than an inpatient endovascular intervention. Overall, 106
of 110 of our patients (96%) had patent subclavian veins during our
follow-up interval, were asymptomatic, and back to their previous active
lifestyle.
Type B Thoracic Aortic Dissection: Open vs Endovascular Repair
Teviah Sachs, Robert Hagberg, Frank Pomposelli, Allen Hamdan, Mark
Wyers, Kristina Giles, and Marc Schermerhorn, From Beth Israel Deaconess
Medical Center. Boston, Mass
Background: This study assessed morbidity and mortality in patients
with type B thoracic aortic dissection (TADB) who undergo operative repair.
Methods: We queried the Nationwide Inpatient Sample (NIS) data-
base, examining all records between 2005 and 2007. Using International
Classification of Diseases (9th ed) diagnosis codes, we selected patients who
underwent an open repair or an endovascular stent graft repair for a diagno-
sis of TAD. We isolated only those patients undergoing repair for TADB by
excluding patients with diagnosis codes for aortic aneurysm and procedure
codes for cardioplegia or for operations on vessels of the heart or valves. We
compared demographics and comorbidities, as well as adjusted complica-
tions and mortality between the cohorts.
Table I. Demographics and comorbidities for
endovascular stent graft vs open repair
Variable Total
Endovascular Open repair
PNo. Yrs or % No. Yrs or %
Average age 8883 1427 62.2 yrs 7456 59.8yrs .065
Female 8883 503 35 2283 31 .168
Prior myocardial infarction 3334 45 6 87 3 .114
Chronic pulmonary disorders 3334 161 22 454 17 .206
Diabetes 3334 90 12 163 6 .063
Hypertension 3334 533 73 1517 58 .015
Neurologic disorders or paralysis 3334 24 3 201 8 .067
Peripheral vascular disease 3334 295 40 646 25 .005
Renal failure 3334 95 13 274 11 .367
Table II. Outcomes for endovascular stent graft vs open
repair
Outcome Total
Endo
(n  1427)
Open
(n  7456)
OR (95% CI) PNo. (%) No. (%)
Death 318 145 (10) 1416 (19) 2.25 (1.32-3.81) .001
LOS median 9.63
days
4652 605 (42) 4047 (54) 1.67 (1.14-2.44) .009
Hemorrhage 1061 39 (3) 1022 (14) 5.45 (2.38-12.51) .0001
Cardiac complication 1160 82 (6) 1077 (14) 2.22 (1.31-3.79) .004
Genitourinary
complication
528 29 (2) 499 (7) 3.27 (1.15-9.29) .025
Stroke 418 36 (3) 381 (5) 1.6 (0.61-4.19) .39
Peripheral vascular
complication
121 25 (2) 96 (1) 1.23 (0.18-8.31) .85CI, Confidence interval; LOS, length of stay. OR, odds ratio.
